Enhanced neuroprotective and antidepressant activity of curcumin-loaded nanostructured lipid carriers in lipopolysaccharide-induced depression and anxiety rat model

Rubab, Sana; Naeem, Komal; Rana, Isra; Khan, Namrah; Afridi, Maryam; Ullah, Izhar; Shah, Fawad Ali; Sarwar, Sadia; Din, Fakhar ud; Choi, Ho-Ik; Lee, Cheol-Ho; Lim, Chang-Wan; Alamro, Abir; Kim, Jin‐Ki; Zeb, Alam

doi:10.1016/j.ijpharm.2021.120670

Cited by 42 publications

(21 citation statements)

References 69 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To examine how anxiety and depression comorbid by neuropathic pain differ from pure anxiety and depression, We constructed the depression model rats by intraperitoneal injection of lipopolysaccharide (LPS, 500 μg/kg) into the rats ( Rubab et al, 2021 ; Figure 9A ). After 14 days, we found that PWT and PWL did not change significantly in LPS rats ( Figure 9B ).…”

Section: Resultsmentioning

confidence: 99%

The cAMP Response Element- Binding Protein/Brain-Derived Neurotrophic Factor Pathway in Anterior Cingulate Cortex Regulates Neuropathic Pain and Anxiodepression Like Behaviors in Rats

Wen

et al. 2022

Front. Mol. Neurosci.

View full text Add to dashboard Cite

Neuropathic pain is often accompanied by anxiety and depression-like manifestations. Many studies have shown that alterations in synaptic plasticity in the anterior cingulate cortex (ACC) play a critical role, but the specific underlying mechanisms remain unclear. Previously, we showed that cAMP response element-binding protein (CREB) in the dorsal root ganglion (DRG) acts as a transcription factor contributing to neuropathic pain development. At the same time, brain-derived neurotrophic factor (BDNF), as important targets of CREB, is intricate in neuronal growth, differentiation, as well as the establishment of synaptic plasticity. Here, we found that peripheral nerve injury activated the spinal cord and ACC, and silencing the ACC resulted in significant relief of pain sensitivity, anxiety, and depression in SNI rats. In parallel, the CREB/BDNF pathway was activated in the spinal cord and ACC. Central specific knockdown and peripheral non-specific inhibition of CREB reversed pain sensitivity and anxiodepression induced by peripheral nerve injury. Consequently, we identified cingulate CREB/BDNF as an assuring therapeutic method for treating neuropathic pain as well as related anxiodepression.

show abstract

Section: Resultsmentioning

confidence: 99%

The cAMP Response Element- Binding Protein/Brain-Derived Neurotrophic Factor Pathway in Anterior Cingulate Cortex Regulates Neuropathic Pain and Anxiodepression Like Behaviors in Rats

Wen

et al. 2022

Front. Mol. Neurosci.

View full text Add to dashboard Cite

show abstract

“…The antidepressant efficacy of curcumin in modulating depressive behavior in different animal models has been shown in a large number of behavioral studies. Most of the studies reported improved performance in the forced swimming test [ 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 ], increased locomotor activity in the open field test [ 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 , 64 ], decreased anxiety in the elevated plus maze test [ 57 , 59 , 64 , 65 , 66 ], improved anhedonia in the sucrose preference test [ 51 , 52 , 54 , 56 , 58 , 62 , 67 , 68 , 69 , 70 , 71 , 72 ,…”

Section: Resultsmentioning

confidence: 99%

“…NA was also incremented in five studies [ 46 , 49 , 55 , 63 , 86 ]. In addition, curcumin has been claimed to present beneficial effects on reducing inflammatory cytokines (IL-1β, IL-6) [ 60 , 63 , 69 , 70 , 71 , 76 , 77 , 91 ], reducing the NF-κB-iNOS-COX-2-TNF-α inflammatory signaling pathway [ 39 , 51 , 52 ], and modulating the levels of antioxidant markers, such as monoamine oxidase (MAO), malondialdehyde (MDA), CAT, or SOD [ 43 , 56 , 57 , 62 , 65 , 66 , 82 , 84 , 88 ]. Furthermore, the BDNF is incremented by curcumin treatment [ 36 , 39 , 47 , 51 , 54 , 58 , 66 , 67 , 77 , 78 , 90 ].…”

Section: Resultsmentioning

confidence: 99%

“…In addition, curcumin has been claimed to present beneficial effects on reducing inflammatory cytokines (IL-1β, IL-6) [ 60 , 63 , 69 , 70 , 71 , 76 , 77 , 91 ], reducing the NF-κB-iNOS-COX-2-TNF-α inflammatory signaling pathway [ 39 , 51 , 52 ], and modulating the levels of antioxidant markers, such as monoamine oxidase (MAO), malondialdehyde (MDA), CAT, or SOD [ 43 , 56 , 57 , 62 , 65 , 66 , 82 , 84 , 88 ]. Furthermore, the BDNF is incremented by curcumin treatment [ 36 , 39 , 47 , 51 , 54 , 58 , 66 , 67 , 77 , 78 , 90 ]. Other effects of curcumin have been described in different animal models of depression, such as an interaction with glutamate N-Methyl-D-Aspartate (NMDA) receptors [ 37 ], an inhibition of Ca +2 channels [ 74 ], an increased level of corticosterol and cortisone in plasma [ 64 ], or an altered lipid metabolism [ 75 ], or an upregulation of the insulin receptor IRS-1 and protein kinase-B (PKB) in the liver [ 73 ].…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

An Update on the Exploratory Use of Curcumin in Neuropsychiatric Disorders

et al. 2022

View full text Add to dashboard Cite

Curcumin is a polyphenol extracted from the rhizome of the turmeric plant. Beyond its common use as a culinary spice in Eastern Asia, curcumin has been proposed as a therapeutic compound due to its antioxidant, anti-inflammatory and neuroprotective properties. Thus, its efficacy has been evaluated in various inflammatory-based psychiatric disorders, such as schizophrenia, depression, or autism. Our aim is to review those preclinical and clinical studies carried out in psychiatric disorders whose therapeutic approach has involved the use of curcumin and, therefore, to discern the possible positive effect of curcumin in these disorders. Preclinical studies and completed clinical trials of curcumin for psychiatric disorders published from January 2005 to October 2021 were identified through searching relevant databases until 31st October 2021. Sixty-five preclinical studies and 15 clinical trials and open-label studies were selected. Results showed a bias toward studies in depression and, to a lesser extent, schizophrenia. In all disorders, the results were positive in reducing psychiatric deficits. Despite the considerable number of beneficial outcomes reported, the small number of trials and the heterogeneity of protocols make it difficult to draw solid conclusions about the real potency of curcumin in psychiatric disorders.

show abstract

“…The PXRD patterns of all the samples were obtained between the 2 θ range of 10–80 at a scanning rate of 4 /min. The instrument was operated at 40 mA current and 40 kV voltage (Rubab et al., 2021 ).…”

Section: Methodsmentioning

confidence: 99%

Eplerenone nanocrystals engineered by controlled crystallization for enhanced oral bioavailability

et al. 2021

Self Cite

View full text Add to dashboard Cite

Enhanced neuroprotective and antidepressant activity of curcumin-loaded nanostructured lipid carriers in lipopolysaccharide-induced depression and anxiety rat model

Cited by 42 publications

References 69 publications

The cAMP Response Element- Binding Protein/Brain-Derived Neurotrophic Factor Pathway in Anterior Cingulate Cortex Regulates Neuropathic Pain and Anxiodepression Like Behaviors in Rats

The cAMP Response Element- Binding Protein/Brain-Derived Neurotrophic Factor Pathway in Anterior Cingulate Cortex Regulates Neuropathic Pain and Anxiodepression Like Behaviors in Rats

An Update on the Exploratory Use of Curcumin in Neuropsychiatric Disorders

Eplerenone nanocrystals engineered by controlled crystallization for enhanced oral bioavailability

Contact Info

Product

Resources

About